ABMD - Abiomed, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
182.98
-1.48 (-0.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close184.46
Open185.14
Bid176.00 x 1100
Ask182.98 x 800
Day's Range181.90 - 187.50
52 Week Range155.02 - 364.31
Volume548,006
Avg. Volume913,903
Market Cap8.262B
Beta (5Y Monthly)0.27
PE Ratio (TTM)38.20
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is Abiomed, Inc.'s (NASDAQ:ABMD) CEO Pay Justified?
    Simply Wall St.

    Is Abiomed, Inc.'s (NASDAQ:ABMD) CEO Pay Justified?

    In 2004 Mike Minogue was appointed CEO of Abiomed, Inc. (NASDAQ:ABMD). This report will, first, examine the CEO...

  • GuruFocus.com

    Global Markets Turn Red Tuesday

    Halliburton falls on fourth-quarter results Continue reading...

  • Extreme greed in the stock market is producing a bad setup as earnings season starts
    MarketWatch

    Extreme greed in the stock market is producing a bad setup as earnings season starts

    Earnings are the single best guide in the stock market in the long term. Only 8% of the strong move up in the stock market last year was attributable to earnings. The rest was triggered by the Federal Reserve reversing its policy of raising interest rates, which boosted sentiment, especially among the momo (momentum) crowd.

  • ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View
    Zacks

    ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View

    ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.

  • Barrons.com

    The Dow Is Up 80 Points Because There Is Little Holding It Back

    The three major U.S. stock market indexes rose as investors looked ahead to Wednesday’s signing of the initial U.S.-China trade pact.

  • GuruFocus.com

    All 4 of Analysts' Favorite Stocks Fell Last Year

    The stocks that Wall Street analysts most adored a year ago all fell Continue reading...

  • TheStreet.com

    Abiomed Sinks After Heart Pump Maker Cuts Full-Year Revenue Forecast

    Abiomed's new, lower estimate for full-year revenue comes in well below analysts' estimates.

  • Why Abiomed (ABMD) Could Beat Earnings Estimates Again
    Zacks

    Why Abiomed (ABMD) Could Beat Earnings Estimates Again

    Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why
    Investor's Business Daily

    These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why

    Medical technology companies are rising bullishly in 2020. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.

  • Top 5 Best-Performing Stocks of the Past Decade
    GuruFocus.com

    Top 5 Best-Performing Stocks of the Past Decade

    These S&P; 500 members wowed investors over the last 10 years Continue reading...

  • 5 Best-Performing Technology Stocks of a Decade
    Zacks

    5 Best-Performing Technology Stocks of a Decade

    Robust demand for memory chips and other cutting-edge technology products are fueling growth in the space.

  • Should You Like Abiomed, Inc.’s (NASDAQ:ABMD) High Return On Capital Employed?
    Simply Wall St.

    Should You Like Abiomed, Inc.’s (NASDAQ:ABMD) High Return On Capital Employed?

    Today we'll look at Abiomed, Inc. (NASDAQ:ABMD) and reflect on its potential as an investment. To be precise, we'll...

  • These are the 20 best-performing stocks of the past decade, and some of them will surprise you
    MarketWatch

    These are the 20 best-performing stocks of the past decade, and some of them will surprise you

    DEEP DIVE As we approach the end of 2019, it’s time not only for year-end lists, but end-of-decade lists. U.S. stocks have had what can only be called an excellent decade. MarketWatch will feature a number of forward-looking articles building on the past decade’s action.

  • Stock market news: December 24, 2019
    Yahoo Finance

    Stock market news: December 24, 2019

    U.S. stocks rose to kick off a holiday-shortened session, extending a December advance for the three major indices.

  • Top Stocks Of The 2010s
    Zacks

    Top Stocks Of The 2010s

    Top Stocks Of The 2010s

  • 6 Underperforming Guru Stocks
    GuruFocus.com

    6 Underperforming Guru Stocks

    Juniper Networks and Guardant Health on the list Continue reading...

  • 10 Stocks to Buy That Lost 8%-Plus in the Past Month
    InvestorPlace

    10 Stocks to Buy That Lost 8%-Plus in the Past Month

    As I write this, there are less than two weeks left until Christmas Day. Though there are only a few days of trading left until the end of the year, it's not too late to boost your portfolio's 2019 performance with these cheap stocks to buy.How good a year has it been?The S&P 500 is up 27.5% year to date (YTD). Every sector, including energy, are solidly in the positive with information technology stocks leading the way, up 44%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo far in December, S&P 500 stocks aren't doing nearly as well, up 2.6% -- with a good chunk of that positive return coming today. Each of the stocks selected for this list of stocks to buy has a market cap of $2 billion or more and has lost 10% or more at some point over the past month.Out of 1,825 stocks with a market cap greater than $2 billion, only 62 had lost 10% or more in a month as of Dec. 12. Even after today's gains, these stocks remain in the red over the past 30 days. * 7 'A'-Rated Stocks to Buy Before 2020 Here are my top 10 stocks to buy from the group of 62. Stocks to Buy: Abiomed (ABMD)Source: Pavel Kapysh / Shutterstock.com So far, 2019 has been a downer for long-time shareholders of Abiomed (NASDAQ:ABMD).Down 46% YTD, ABMD stock has had better performances in recent years. The maker of Impella heart pumps has generated an annualized total return of 36% for loyal shareholders over the past decade.If you're one of the lucky ones who've owned its stock for the past 10 years, congratulations on a buy well done. If you're one of the unlucky ones who got in at some point during 2019, be patient, your turn will come.As I stated in my recent article about the seven S&P 500 stocks I expect to deliver over the next decade, just as they did this past decade, Abiomed ought to continue to gain market share as the population continues to age.Down 20% over the past month, take advantage of Abiomed's correction and buy some more. A.O. Smith (AOS)Source: Shutterstock A.O. Smith (NYSE:AOS) is one of my all-time favorite stocks.Sure, there are plenty of names I could list off that I've recommended over the years that have done better than the Wisconsin-based manufacturer of water heaters, boilers and water softeners. Still, there are very few that I would consider "stick-in-a-drawer" type stocks that you can forget about for a decade or more and still make out okay.AOS is one such stock.Over the past decade, A.O. Smith has generated an annualized total return of 21.4%. Yet, it's been unable to break out of single-digit gains in 2019. Up 9% YTD, the 8% decline over the past month hasn't helped one iota.In October, my InvestorPlace.com colleague, Ian Bezek, made AOS one of seven mid-cap stock selections. Bezek reasoned that the trade war is killing the company. Once an agreement is reached, the sky's the limit for AOS. In the meantime, you can enjoy the Dividend Aristocrat's 2.1% yield. * 5 Tech Stocks That Could Be the Next M&A Target The one thing I know is you can't keep a good dog down. A.O. Smith's stock trajectory will soon turn to the stars. When it does, you'll be glad I mentioned it. Dell Technologies (DELL)Source: Jonathan Weiss / Shutterstock.com It's hard to believe that Michael Dell, CEO of Dell Technologies (NYSE:DELL), is 54 years old. It seems like only yesterday we were reading about this up-and-comer who started a computer business in his dorm room.And while the Texas entrepreneur has had his ups and downs in recent years, the fact Dell stock has lost more than 11% in the past month, do provide tech investors with a much more attractive entry point.InvestorPlace.com contributor Vince Martin owns Dell stock. He recently suggested that the company's 81% stake in VMware (NYSE:VMW) could be worth substantially more in the future should Dell decide to buy out the remaining minority shareholders.The reality is that Dell generates significant free cash flow -- the company's trailing 12-month free cash flow of nearly $5.9 billion is 150% of its net income -- which makes the correction over the past month an opportune time to make money on one of the few tech stocks performing in 2019. DuPont de Nemours (DD)Source: ricochet64 / Shutterstock.com For those unaware, DuPont de Nemours (NYSE:DD) used to be part of DowDuPont; the company created when Dow and DuPont merged in 2017, only to be demerged two years later into three separate companies.As a result of the de-merger, DD stock began trading on the NYSE on June 3. It joined former stablemates Dow (NYSE:DOW) and Corteva (NYSE:CTVA) as publicly traded, independent companies.DuPont is a specialty chemical maker whose products include advanced plastics, adhesives and enzymes for the production of cars, electronics and many consumer goods. Dow is responsible for commodity chemicals and Corteva makes seeds.Together, the three entities were one massive company. Separately, though, they're still three incredibly complex businesses.In the past month, DD stock has shed more than 10% of its value. Since becoming an independent company in June, DuPont de Nemours stock had a quick burst out of the gate, closing its first day of trading at $76.10, up 18%. It has since lost all of those gains and then some. * 3 Reasons Why Trade Desk Stock Is Advertising's Future DuPont and the other two companies were de-merged specifically to add value for DowDupont shareholders. I would expect some of those benefits to be realized in 2020. Foot Locker (FL)Source: Roman Tiraspolsky / Shutterstock.com Foot Locker (NYSE:FL) has traded below $40 on three occasions since late 2013.On the first occasion, in December 2013, the sneaker and apparel retailer broke through $40 for the very first time after recovering from the 2008 recession, which saw its stock drop to less than $6.The second occasion was in September 2017, and the third and final time dropping below $40 came in August. So, except for a brief November rally, FL stock been in the dumps since the fall.On Nov. 22, Foot Locker reported healthy third-quarter revenue and earnings per share (EPS) numbers. On the top line, sales rose 3.9% to $1.9 billion while on the bottom line, EPS increased 18.9% to $1.13. Also, same-store sales grew by 5.7%, which suggests the company is making progress, positioning itself to compete in the changing world of retail.Unfortunately, the company's prediction of flat same-store sales growth in the fourth quarter -- down from a 9.7% increase in last year's fourth quarter and worse than the 2% growth estimate from analysts -- sent FL stock spiraling lower.As a result, Foot Locker's total return over the past month is -18.9%, considerably worse than the 2.6% gain for the U.S. total market.Foot Locker tends to be conservative when providing quarterly guidance, so I wouldn't be surprised if same-store sales weren't favorable in the fourth quarter. Hess (HES)Source: rafapress / Shutterstock.com Of all the stocks on this list, Hess (NYSE:HES) is the one company whose 2019 performance couldn't be characterized as anything but successful. Despite a 9% correction over the past month, HES has generated a YTD total return of 56% -- doubling the performance of the U.S. total market.Hess has severely underperformed in recent years, generating a five-year annualized total return of -0.3%, almost 12 percentage points worse than the total U.S. market. Reversion to the historical mean was bound to happen at some point.In 2013, Hess began the arduous process of selling off some of its assets to focus on energy production and exploration. Activist investor Elliott Management pushed management to become an energy pure-play.The only problem with that plan is that oil and gas exploration hasn't been nearly as profitable over the past five years due to weaker prices. That said, it has managed to perform exceptionally well in a challenging business environment. * These 7 S&P 500 Stocks Will Deliver a Repeat Performance in the Next Decade The recent drop is likely attributable to investors taking profits. Kohl's (KSS)Source: Sundry Photography/Shutterstock.com YTD, Kohl's (NYSE:KSS) has a total return of 23.2%. In the past month, it has lost nearly 14%. Yet, Retail Dive named CEO Michelle Gass, its retail executive of the year.Of course, Retail Dive isn't nearly as concerned as InvestorPlace.com readers about the performance of its stock. It's more interested in innovation, and on that front, it feels Gass has delivered in a big way.One of its most significant initiatives in 2019 was the rollout of its returns program in partnership with Amazon (NASDAQ:AMZN). A pilot project since 2017, this year, Gass went all in, providing the e-commerce giant with 1,150 locations across the U.S. where customers could return products they weren't happy with.As I noted in October, this was a partnership that would prove beneficial for both companies.As for Christmas, Kohl's is staying open 24 hours a day from the morning of Dec. 20 to 6 p.m. on Christmas Eve. I don't know how many extra shoppers it will snag with this approach, but it's another sign Gass is trying every lever at her disposal to drive sales in a weak department store environment.While there are several other retail executives worthy of this award, Gass is facing extraordinary challenges.I expect a full recovery in 2020. MasTec (MTZ)Source: IgorGolovniov / Shutterstock.com MasTec (NYSE:MTZ) was sailing along in 2019 and then came November, and the wheels fell off.Since then, MTZ's given back all of the gains it made in October. Down almost 15% in the past month, the infrastructure construction stock has still delivered a YTD total return of 49%, easily beating the markets as a whole.At the end of October, MasTec reported Q3 2019 results that beat analyst estimates. On the top line, it had an EPS of $1.73, 10 cents clear of the consensus and 30% higher than its profits last year. In the past four quarters, it has beaten the estimate on all four occasions.On the bottom line, MasTec's revenues were $2.02 billion, 5.3% lower than the consensus estimate of $2.13 billion. However, it did manage to grow sales 2% over the same period a year ago.Not to worry.Through the first nine months of its fiscal year, Mastec's revenues have grown by healthy 9.7%, while its adjusted EBITDA has risen by 20.5%.With a diversified group of four revenue streams -- Communications, Oil and Gas, Electrical Transmission, and Power Generation/Industrial -- MasTec's business is insulated from any single industry going into a slowdown. * The 10 Worst Dividend Stocks of the Decade As long as America continues to have tremendous infrastructure needs, MasTec stock should continue to do very well. PagSeguro Digital (PAGS)Source: rafastockbr / Shutterstock.com There are several things I like about Brazilian payments company PagSeguro Digital (NYSE:PAGS).First, I've been a big believer in Latin America for many years. Here's what I said about the region in July 2012:"As Brazil prepares to host the 2016 Summer Olympics, some in Latin America suggest economic gains made since the beginning of the global financial crisis have benefited the rich and powerful at the exclusion of everyone else. Further, the structural changes necessary to build a flourishing middle class have yet to appear, making these gains illusory at best."While I do agree that investors should be cognizant of the continuing disconnect that exists between the wealth of these countries and the average citizen, the future remains brighter for Latin America than it's ever been. Tread carefully, but don't let the rhetoric spoil one of the best investment opportunities anywhere.Everything I said back then still applies today. The opportunities in Latin America are endless.Secondly, while investors didn't seem to like PagSeguro's third-quarter results delivered in November -- PAGS stock has seen an 13% decline over the past month -- I see a business that's growing at a very healthy pace.Total revenues grew 28.7% in the quarter on the top line while on the bottom, its net income increased by 47.5%. Furthermore, its total payment volume (TPV) jumped 45% in the quarter to $7.2 billion.As a payments processor, you want to see higher TPV. In the third quarter, it grew the metric just fine.Forget the investor reaction. This is a buying opportunity. Rollins (ROL)Source: Shutterstock The great thing about prognosticating about stocks is that you've got nowhere to hide. If you make a recommendation about a particular stock and it tanks, your words are permanently on display -- making it easy for readers to second-guess your opinions.At the end of October, I recommended Rollins (NYSE:ROL) along with nine other stocks investors should consider regardless of their latest quarterly earnings.Rollins specializes in pest control. Its Orkin brand serves more than 1.7 million residential and commercial customers on every continent except Antarctica. Many of its customers have stuck with it for decades, which allows it to generate a significant amount of recurring revenue.I love the fact that the Rollins family, who own more than 50% of its stock and are intimately involved with the company, understand the importance of customer service in a business that you usually wouldn't consider customer friendly.Once you've got a good pest control person, especially if you're in real estate, it's hard to let them go knowing the importance of pest-free environments.The longer you hold Rollins stock, the better your results are going to be. It's the ultimate buy-and-hold stock.Down almost 9% over the past month, it's looking like Rollins will have its first year of negative calendar returns in many a moon. Don't miss out on this buying opportunity.At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 'A'-Rated Stocks to Buy Before 2020 * 7 of the Decade's Fastest-Growing Dividend Stocks * 5 Cheap Dividend Stocks With High Yields And Annual Increases The post 10 Stocks to Buy That Lost 8%-Plus in the Past Month appeared first on InvestorPlace.

  • Barrons.com

    The Dow Is Up 175 Points Because the Trade War News Is Sinking In

    The three major U.S. stock market indexes were solidly in the green as investors seemed to take a risk-on approach after an initial trade deal between the U.S. and China was announced last week.

  • Hedge Funds Are Selling ABIOMED, Inc. (ABMD)
    Insider Monkey

    Hedge Funds Are Selling ABIOMED, Inc. (ABMD)

    Does ABIOMED, Inc. (NASDAQ:ABMD) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]

  • The stock market's biggest winners and losers of the past decade
    Yahoo Finance

    The stock market's biggest winners and losers of the past decade

    With the 2010s officially drawing to a close, Yahoo Finance took a look at some of the biggest S&P 500 winners and losers of the past decade based on price returns.

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • Investopedia

    4 Big Name Stocks To Weigh Selling Now Before Losses Widen

    Macy's, 3M, Occidental and Abiomed are down sharply in 2019, and tax loss selling may send them plunging yet more.

  • Benzinga

    Cramer Weighs In On Biogen, Caterpillar And More

    Jim Cramer spoke on CNBC's "Mad Money Lightning Round" about Biogen Inc (NASDAQ: BIIB ). He is concerned about the stock because a Baird analyst expressed his skepticism about Biogen's Alzheimer's ...

  • Did You Miss Abiomed's (NASDAQ:ABMD) Whopping 426% Share Price Gain?
    Simply Wall St.

    Did You Miss Abiomed's (NASDAQ:ABMD) Whopping 426% Share Price Gain?

    Abiomed, Inc. (NASDAQ:ABMD) shareholders have seen the share price descend 11% over the month. But that does not...

  • Barrons.com

    The S&P 500 Notches Its 26th Record This Year Before Falling Back

    “Over the last couple of months, we’ve seen equity investors getting pulled in reluctantly to a rising market,” says Citi’s Tobias Levkovich.